Home / Pipeline – BC007

Pipeline – BC007

Pipeline and BC007 Mode of Action

Our candidate BC007 is a non-modified DNA aptamer out of a family of aptamers that bind to and lead to the neutralization of autoantibodies that are directed against G-protein-coupled receptors (GPCR-AABs). BC007 binds to ß1-adrenergic-receptor-autoantibodies.

BC 007 was successfully tested in a Phase-1 clinical trial. This study included a sub-group of subjects that are tested positive for GPCR-autoantibodies and which are otherwise healthy. The study design allowed for the proof that BC007 can neutralize GPCR-autoantibodies in humans. The full study design is published on clinicaltrials.gov

After successful completion of Phase 1/1b, we initiated a multi-center, randomised, controlled Phase 2 study in heart failure patients.


Mode of Action

This video sequence demonstrates the mechanism of action of BC007

Data Privacy / Datenschutzerklärung